Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Virology

Background:

• Imatinib is a standard therapy for chronic myeloid leukemia (CML), but resistance and intolerance affect 26-37% of patients.
• Apoptin, a viral protein, exhibits selective toxicity towards cancer cells and can inhibit hyperactive kinases like BCR-ABL1.
• Previous research identified an apoptin segment interacting with BCR-ABL1's SH3 domain, negatively regulating its kinase activity.

Purpose of the Study:

• To investigate the therapeutic potential of apoptin-derived peptides for CML treatment.
• To establish the minimal region of apoptin responsible for BCR-ABL1 interaction.
• To evaluate the efficacy of an apoptin decapeptide in inhibiting BCR-ABL1 and its downstream targets.

Main Methods:

• Characterization of the minimal apoptin interaction domain with BCR-ABL1.
• Assessment of apoptin decapeptide's ability to inhibit BCR-ABL1 downstream target c-Myc.
• Evaluation of synthetic apoptin's effect on cell proliferation in murine and human CML cell lines (32Dp210, K562).
• Ex vivo testing in imatinib-sensitive and imatinib-resistant CML patient samples.

Main Results:

• The apoptin decapeptide effectively inhibits BCR-ABL1 kinase activity and downstream target c-Myc.
• The decapeptide demonstrates comparable efficacy to full-length apoptin and imatinib in inhibiting c-Myc.
• Synthetic apoptin significantly inhibits proliferation in CML cell lines and patient samples, including imatinib-resistant cases.

Conclusions:

• Apoptin-derived decapeptide represents a promising therapeutic agent for chronic myeloid leukemia.
• This peptide offers a potential new treatment strategy for patients with imatinib resistance or intolerance.
• Apoptin-based therapies, alone or in combination, could become a viable curative option for CML.